Compositions for inhibition of quiescin sulfhydryl oxidase (qsox1) and uses of same

Abstract

A method of inhibiting or preventing laminin assembly in a basement membrane is disclosed. The method comprising contacting a tissue with an agent which inhibits QSOX1 activity or expression, thereby inhibiting or preventing laminin assembly in the basement membrane.

What is claimed is: 
     
         1 . A method of inhibiting or preventing laminin assembly in a basement membrane, the method comprising contacting a tissue with an anti QSOX1 antibody, thereby inhibiting or preventing laminin assembly in the basement membrane. 
     
     
         2 . The method of  claim 1 , wherein said tissue is a tumor tissue. 
     
     
         3 . The method of  claim 1 , wherein said antibody is MAb492.1 and comprises complementarity determining regions (CDRs) SEQ ID NOs: 29-34. 
     
     
         4 . The method of  claim 1 , wherein said antibody fragment is scFV492.1 and comprises CDRs SEQ ID NOs: 29-34. 
     
     
         5 . A method of inhibiting cell migration via a laminin-comprising basement membrane, the method comprising contacting a tissue with an anti QSOX1 antibody, thereby inhibiting the cell migration via the laminin-comprising basement membrane. 
     
     
         6 . The method of  claim 1 , wherein said cell is a tumor cell. 
     
     
         7 . The method of  claim 5 , wherein said tissue is a tumor tissue. 
     
     
         8 . The method of  claim 1 , wherein said tissue comprises fibroblasts. 
     
     
         9 . The method of  claim 5 , wherein said method is performed in-vivo. 
     
     
         10 . A method of treating a laminin-associated disease or condition in a subject in need thereof the method comprising administering to the subject a therapeutically effective amount of an anti QSOX1 antibody, thereby treating the laminin-associated disease or condition in the subject. 
     
     
         11 . The method of  claim 10 , wherein said laminin-associated disease or condition is a tumor. 
     
     
         12 . The method of  claim 11 , wherein said tumor is a metastasizing solid tumor. 
     
     
         13 . The method of  claim 11 , wherein said tumor is an adenocarcinoma. 
     
     
         14 . The method of  claim 11 , wherein said tumor is selected from the group consisting of a prostate cancer, a lung cancer, a breast cancer, a cervical cancer, a urachus cancer, a vaginal cancer, a colon cancer, an esophagus cancer, a pancreatic cancer, a throat cancer, a stomach cancer and a myeloid leukemia. 
     
     
         15 . The method of  claim 10 , wherein said laminin-associated disease or condition is associated with fibrosis. 
     
     
         16 . The method of  claim 1 , wherein said laminin comprises an alpha 4 chain. 
     
     
         17 . The method of  claim 1 , wherein said laminin is laminin-411 or laminin-421. 
     
     
         18 . The method of  claim 10 , wherein said anti QSOX1 antibody is directed towards amino acid coordinates 34 to 266 of said QSOX1. 
     
     
         19 . The method of  claim 18 , wherein said antibody is MAb492.1 and comprises complementarity determining regions (CDRs) SEQ ID NOs: 29-34. 
     
     
         20 . The method of  claim 18 , wherein said antibody fragment is scFV492.1 and comprises CDRs SEQ ID NOs: 29-34.